Aurinia Pharmaceuticals Inc. logo AUPH - Aurinia Pharmaceuticals Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 11
HOLD 4
SELL 0
STRONG
SELL
0
| PRICE TARGET: $12.60 DETAILS
HIGH: $16.00
LOW: $6.00
MEDIAN: $13.00
CONSENSUS: $12.60
DOWNSIDE: 24.05%

About Aurinia Pharmaceuticals Inc. (https://www.auriniapharma.com)

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Key Executives

NAME TITLE DOB SALARY
Peter S. Greenleaf Consultant 1970 $1,700,080 USD
Stephen Robertson Chief Legal Officer, Corporate Secretary & Chief Compliance Officer 1982 $923,480 USD
Michael S. Hearne Chief Financial Officer 1963 $866,870 USD
Kevin C. Tang Chairman & CEO 1967
Ryan Cole Chief Operating Officer 1987
Stewart Kroll Chief Development Officer 1959
Thomas Wei Chief Scientific Officer 1976

Company Peers

Peer analysis pending, check back in 1-2 minutes.